Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Salman R. Punekar, Elaine Shum, Cassandra Mia Grello, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study
Qiang Cao, Jinyi Zhu, Xinyan Wu, et al.
Journal of Cancer (2024) Vol. 15, Iss. 7, pp. 2024-2032
Open Access | Times Cited: 13
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
Julien Ancel, Valérian Dormoy, Béatrice Nawrocki‐Raby, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Xin Zhang, Xuemei Wang, Lijian Hou, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects
Ganggang Bai, Chuance Sun, Ziang Guo, et al.
Seminars in Cancer Biology (2023) Vol. 95, pp. 13-24
Closed Access | Times Cited: 16
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Sun Min Lim, Solange Peters, A.L. Ortega Granados, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
Lanyi Nora Chen, Alexander Z. Wei, Catherine A. Shu
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 13
Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer
Eleonora Martinis, Carolina Ricci, Caterina Trevisan, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1969-1969
Open Access | Times Cited: 13
Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer
Li Liu, Shuo Zhang, Haiyan Yang, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma
Chao‐Yan Yao, Hang-Tian Tao, Jinjin He, et al.
Molecular Medicine (2025) Vol. 31, Iss. 1
Open Access
Intramuscular CMT‐167 Tumours Produce a Mild Cachexia Phenotype in C57BL/6J Mice
Bryan Remaily, Trang T. Vu, Justin Thomas, et al.
Deleted Journal (2025) Vol. 8, Iss. 1
Open Access
A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer
Serafeim‐Chrysovalantis Kotoulas, Dionysios Spyratos, Κonstantinos Porpodis, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 882-882
Open Access
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
Luyao Wang, Zongxing Yang, Fucheng Guo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975–2022 with insights on the impact of COVID-19
Hiroki Yamamoto, Masayuki Shirasawa, Katsuhiko Naoki
International Journal of Clinical Oncology (2025)
Closed Access
Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach
Paweł Zieliński, Maria Stępień, Hanna Chowaniec, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 587-587
Open Access
Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Caterina Cascini, Chiara Ratti, Laura Botti, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 10
Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices
Kátia Roque, Rossana Ruiz, Luís Más, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4547-4547
Open Access | Times Cited: 9
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
Αreti Strati, Panagiota Economopoulou, Evi Lianidou, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1768-1768
Open Access | Times Cited: 8
The Cross-Scale Association between Pathomics and Radiomics Features in Immunotherapy-Treated NSCLC Patients: A Preliminary Study
Abdou Khadir Dia, Leyla Ebrahimpour, Sevinj Yolchuyeva, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 348-348
Open Access | Times Cited: 2
A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer
Nasser K. Altorki, Bhavneet Bhinder, Alain Borczuk, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101438-101438
Open Access | Times Cited: 2
Classification of the Tumor Immune Microenvironment Using Machine-Learning-Based CD8 Immunophenotyping As a Potential Biomarker for Immunotherapy and TGF-β Blockade in Nonsmall Cell Lung Cancer
Robert J. Pomponio, Hong Wang, Sarah Mitchell Bean, et al.
AI in Precision Oncology (2024) Vol. 1, Iss. 2, pp. 106-118
Open Access | Times Cited: 2
Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer
Hye In Lee, Eun Kyung Choi, Su Ssan Kim, et al.
Radiotherapy and Oncology (2024) Vol. 198, pp. 110383-110383
Closed Access | Times Cited: 2
Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
Vianey Rodríguez-Lara, Giovanny Soca‐Chafre, María Rosa Ávila-Costa, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer
Rodrigo Santiago Moreira, Maríllya Morais da Silva, César Freire de Melo Vasconcelos, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 19, pp. 17651-17661
Closed Access | Times Cited: 5
Trypanosoma cruzi-Derived Molecules Induce Anti-Tumour Protection by Favouring Both Innate and Adaptive Immune Responses
Teresa Freire, Mercedes Landeira, Cecilia Giacomini, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15032-15032
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top